about
Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study.Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History.Familiality of Psychotic Disorders: A Polynosologic Study in Multiplex Families.Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs.Lifetime psychopathological dimensions, cognitive impairment and functional outcome in psychosis.Risk factors, pre-morbid functioning and episode correlates of neurological soft signs in drug-naive patients with schizophrenia-spectrum disorders.Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings.Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis.Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study.Motor abnormalities and cognitive impairment in first-episode psychosis patients, their unaffected siblings and healthy controls.Motor abnormalities in first-episode psychosis patients and long-term psychosocial functioning.Basal ganglia and ventricle volume in first-episode psychosis. A family and clinical study.The association of lifetime insight and cognition in psychosis.The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study.Cannabis use, COMT, BDNF and age at first-episode psychosis.Ten-year stability of self-reported schizotypal personality features in patients with psychosis and their healthy siblings.Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study.A comparative study of the working memory multicomponent model in psychosis and healthy controls.Familial liability to schizophrenia and mood disorders and cognitive impairment in psychosis.Treatment response of neurological soft signs in drug-naïve patients with a first psychotic episode.The meaning of childhood attention-deficit hyperactivity symptoms in patients with a first-episode of schizophrenia-spectrum psychosis.The Cognitive Assessment Interview: A comparative study in first episode and chronic patients with psychosis.Affective versus non-affective first episode psychoses: A longitudinal studyCognitive reserve as an outcome predictor: first-episode affective versus non-affective psychosisSmoking does not impact social and non-social cognition in patients with first episode psychosisUsing the cognitive assessment interview to screen cognitive impairment in psychosisExecutive functioning in schizophrenia spectrum disorder patients and their unaffected siblings: A ten-year follow-up studyInfluence of genetic variability at the COMT gene on TMT-B performance in psychotic patients and their healthy siblingsMotor abnormalities and basal ganglia in first-episode psychosis (FEP)The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory
P50
Q34048566-6F8AB6BC-10C0-44E2-B10D-A9E9BFE1B3D1Q36101350-3BA789BE-2DF5-4F36-B237-52D6CFAFAE44Q36994844-BFDF5705-14C2-4C1C-BEE4-34E7FB6B7E28Q37451422-2C13EFAE-4FF7-4965-84F8-93E8BB516C97Q39298370-7B090FA8-3AB3-4279-80EB-958A63B1EDC7Q43499365-AD90B21D-2EEC-4221-904D-3BAE2BA4F326Q43872699-AA1E1523-969D-421A-BD35-697DC6480081Q45196840-DB93D2A6-1D78-4303-A43D-E6682B5F685FQ47556225-59E55CA3-D3BF-426D-8E6A-BEBED1ED5C53Q47571897-20FCF672-ACBF-414F-A262-22E6362ECF9BQ47582822-B08646F6-C004-4C1C-B056-E00551C176CBQ47625490-8C825C75-858F-4E78-BD61-381218E9F186Q47666310-B66CB10C-4F4F-4585-9B59-7E3BD4912DA8Q47760768-B33E1B8B-B926-49F9-B46D-6996514D7A17Q47802903-7BACA297-7DA1-4D62-93F6-C1A8D1BBD77FQ47812974-73B81DE7-18D0-4777-B70E-89B8B6A4158AQ50447906-B6F94A21-E47B-425B-B5F6-4EE945B7A273Q50449274-3CFBBAE0-EB73-46C3-845B-B4F402B4A8ACQ50582565-3C6C4476-693E-4DB7-81AA-FF3BD7D90339Q50588604-FE8D454C-4AF7-4294-B894-308B37349B0CQ50753991-88BBA056-C9F4-4570-A28A-53DC0C14C389Q51749358-5D0490A5-6FF1-4097-8DBD-E9AD1B1A023AQ54064242-5D501394-3635-4EC1-9AF5-0809E1FD42B4Q60459746-407B0201-F74C-4514-B748-2848A4B43250Q60459750-6CC38CCD-16E4-4463-B540-4EE69AAEAEB0Q60459763-0E224B0C-7D7D-4E67-AC53-1FB913F2E2B2Q60460701-11D69EE9-EFE2-4443-9A41-3B3436D38DA9Q60460713-477334C5-DDD6-44BF-A576-05CF3075E74CQ60460719-BCBB7D44-33C9-4B1D-B60A-BFE315AD6C3AQ89959086-A0E7E0DC-BB50-4B8A-BE8C-04EAFD9C848EQ93192452-F52F8A11-54DE-483C-8AFC-75BBF40B07E3
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Ana M Sánchez-Torres
@en
Ana M Sánchez-Torres
@nl
type
label
Ana M Sánchez-Torres
@en
Ana M Sánchez-Torres
@nl
prefLabel
Ana M Sánchez-Torres
@en
Ana M Sánchez-Torres
@nl
P31
P496
0000-0002-9505-2406